Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dronabinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 10/20 | 1.00 |
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | GPR18 | Q14330 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronabinol SCHEMBL29390424 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13394311 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29349828 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL11375978 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL1227386 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13214137 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL24702729 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL3686519 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL4609 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL22705549 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251947-A1 | STABLE FORMULATIONS OF DRONABINOL | TRYAGx Labs Inc. | 2021-08-19 | — | — | US | claimed |
| EP-4359445-A1 | ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | Joint Stock Company "Biocad" (RU) | 2024-05-01 | — | — | EP | disclosed |
| EP-4319736-A1 | MALIGNANT NEOPLASIS TREATMENT USING PD-1 ANTIBODY COMBINATION | Joint Stock Company "Biocad" (RU) | 2024-02-14 | — | — | EP | disclosed |
| US-20240034764-A1 | IMMUNOCYTOKINE FOR ACTIVATING HUMAN IL-10RA RECEPTOR AND USE THEREOF | JOINT STOCK COMPANY "BIOCAD" (RU) | 2024-02-01 | — | — | US | disclosed |
| EP-4259644-A1 | IMMUNOCYTOKINE FOR ACTIVATING HUMAN IL-10RA RECEPTOR AND USE THEREOF | Joint Stock Company "Biocad" (RU) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022271053-A1 | ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022203552-A1 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO GD2 | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-09-29 | — | — | WO | disclosed |
| US-20220213209-A1 | MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-07-07 | — | — | US | disclosed |
| WO-2022124950-A1 | IMMUNOCYTOKINE FOR ACTIVATING HUMAN IL-10RA RECEPTOR AND USE THEREOF | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-06-16 | — | — | WO | disclosed |
| EP-3875486-A1 | MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20 | Joint Stock Company "Biocad" (RU) | 2021-09-08 | — | — | EP | disclosed |
| US-20190224118-A1 | ORAL GASTRORETENTIVE FORMULATIONS AND USES THEREOF | INTEC PHARMA LTD. (IL) | 2019-07-25 | — | — | US | disclosed |
| EP-3481371-A1 | ORAL GASTRORETENTIVE FORMULATIONS AND USES THEREOF | Intec Pharma Ltd. (IL) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018011798-A1 | ORAL GASTRORETENTIVE FORMULATIONS AND USES THEREOF | INTEC PHARMA LTD. (IL) | 2018-01-18 | — | — | WO | disclosed |
| CN-106573123-A | Methods, devices, and systems for pulmonary delivery of active agents | SYQE医药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106573118-A | Methods, devices, and systems for pulmonary delivery of active agents | SYQE医药有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20080038271-A1 | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | disclosed |
| WO-2006017892-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTIONING | NORTHERN SYDNEY AND CENTRAL COAST AREA HEALTH SERVICE (AU) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251947-A1 | STABLE FORMULATIONS OF DRONABINOL | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885ABHD12 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.